Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Conscious of the importance of strategically aligning our company with patient needs, our R&D efforts are focused on contributing to bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent.Our rigorous drug discovery and development process, and our commitment to improving health through innovation, have resulted in the creation of a pipeline dedicated to areas where we can lead and make a significant impact.
Our lead pipeline product Elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis) and is currently launching a Phase 3 study. This metabolism-related liver disease, which can progress to cirrhosis and even liver cancer, shows a dramatically increasing prevalence worldwide. Elafibranor represents a major hope for patients and their physicians, who currently have no efficient treatment for NASH.
In addition to Elafibranor, our R&D pipeline relies mainly on our world-renowned scientific expertise in gene regulation and nuclear receptors.
It is comprised of multiple drug candidate research programs targeting novel mechanisms of action including the inhibition of RORγ-t.
GENFIT Headquarters
Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos
France
+33 (0)3 20 16 40 00
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Patrick Choay discusses his first foray into the pharmaceutical business world, talks about the highlights of his long and interesting career, his balanced partnership strategy for the Choay Group and…
Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the…
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international…
Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third…
Mr Truelle, the CEO of CDM Lavoisier, a company specialized in the pharmaceutical manufacturing of injectable solutions, reveals that one third of the French population could receive one of the…
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic…
See our Cookie Privacy Policy Here
